生脉六君子汤治疗慢性阻塞性肺疾病稳定期（肺脾两虚证）的临床观察

发布时间：2018-01-24 00:10

本文关键词： 慢阻肺稳定期肺脾两虚证生脉六君子汤临床研究　出处：《山东中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的:本文旨在观察生脉六君子汤治疗慢阻肺稳定期(肺脾两虚证)的疗效,分析其内在机理,探讨其作用机制,为临床治疗提供可靠的理论依据。方法:(1)参照慢阻肺的诊断标准及中医辨证标准,纳入符合标准的患者64名。随机分为试验组、对照组,每组32名。(2)治疗时间为2个月。两组分别给予不同的药物治疗,试验组(生脉六君子汤+常规治疗)、对照组(常规治疗)。观察并记录治疗前后患者的临床疗效、中医症候积分、肺功能(FVC、FEV1pred%)、CAT评分、血清白蛋白、BMI指数、急性加重次数等指标的变化情况,进行数据分析得出结论。(3)实验数据用SPSS17.0软件进行统计学分析。结果:(1)临床疗效:试验组临床总有效率为90%;对照组临床总有效率为70%;试验组优于对照组。(2)中医症候积分:与治疗前比较,两组治疗后中医症候积分均有所降低,其中试验组降低更为明显,P0.05,有统计学意义。(3)肺功能(FVC、FEV1%pred):在改善FVC、FEV1%pred方面,P0.05,两组皆无统计学意义,但从治疗前后数值的变化来看,试验组优于对照组。(4)慢性阻塞性肺疾病评估测试(CAT)评分:两组治疗后较治疗前CAT评分均有所减少,其中试验组评分减少更为明显,P0.05,有统计学意义。(5)血清白蛋白:与治疗前比较,两组治疗后血清白蛋白数值均有所提高,其中试验组提高更为明显,P0.05,有统计学意义。(6)BMI指数:治疗结束后追踪半年,BMI指数方面,与治疗前相比,两组均有所提高,试验组提高更为明显,P0.05,有统计学意义。(7)急性加重次数:治疗结束后追踪半年,试验组在急性加重次数方面明显少于对照组,P0.05,有统计学意义。结论:生脉六君子汤治疗慢阻肺稳定期肺脾两虚证的临床疗效显著,可有效改善患者的临床症状、体征以及营养状态,稳定肺功能,减少急性加重次数,进而提高患者的生活质量。
[Abstract]:Objective: to observe the therapeutic effect of Shengmai Liujunzi decoction on chronic obstructive lung in stable stage (deficiency of lung and spleen), to analyze its internal mechanism and to explore its mechanism. To provide a reliable theoretical basis for clinical treatment. Methods: according to the diagnostic criteria of chronic obstructive pulmonary disease (COPD) and TCM syndrome differentiation criteria, 64 patients who met the criteria were randomly divided into experimental group and control group. The treatment time was 2 months in each group (32 cases). The two groups were given different drug treatment, and the experimental group (Shengmai Liujuntang routine treatment). In the control group (routine treatment), the clinical efficacy, TCM symptom score, pulmonary function, FEV1 predct cat score and serum albumin were observed and recorded before and after treatment. The change of BMI index, acute exacerbation times and so on. Conclusion: the experimental data were statistically analyzed by SPSS17.0 software. Results: clinical efficacy: the total effective rate of the experimental group was 90; In the control group, the total effective rate was 70. The experimental group is better than the control group. 2) TCM symptom score: compared with before treatment, the TCM symptom score of the two groups decreased after treatment, in which the test group decreased more significantly (P0.05). There was no significant difference between the two groups in the improvement of FEV1 Pred. But from the change of the values before and after treatment, the test group was better than the control group. 4) the chronic obstructive pulmonary disease assessment test (CAT) score: the two groups after treatment than before treatment were reduced. The scores of the test group decreased more significantly than that of the control group (P 0.05, P < 0.05). There was significant difference between the two groups in serum albumin: compared with before treatment, the values of serum albumin in both groups were improved. Among them, the experimental group increased significantly (P0.05), there was statistical significance. The BMI index of six months after treatment was followed up half a year after treatment, compared with before treatment, both groups were improved. The treatment group increased P0.05, with statistical significance. 7) the number of acute exacerbations: six months after the end of treatment, the number of acute exacerbations in the trial group was significantly lower than that in the control group (P0.05). Conclusion: Shengmai Liujunzi decoction has a significant clinical effect in the treatment of two deficiency syndrome of lung and spleen in the stable stage of chronic obstructive lung, which can effectively improve the clinical symptoms, signs and nutritional status of the patients, and stabilize the lung function. Reduce the number of acute exacerbation, and then improve the quality of life of patients.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【参考文献】